Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Pneumococcal Vaccine Market Size & Share 2026-2035
Report ID: GMI13337
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Pneumococcal Vaccine Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Pneumococcal Vaccine Market Size
The pneumococcal vaccine market was valued at USD 9.2 billion in 2025, is expected to reach USD 9.9 billion in 2026, is projected to expand at a 5.2% CAGR (2026–2035), and is forecast to reach USD 15.3 billion by 2035.
Pneumococcal Vaccine Market Key Takeaways
Market Leader: Pfizer Inc. led with over 67.1% market share in 2025.
The pneumococcal vaccine market is being reshaped by two demand systems with different economics: premium adult vaccination in high-income healthcare markets and scale-led childhood immunization through public programs. Higher-valency conjugate vaccines are improving the revenue mix in adult care, while national immunization program expansion broadens dose volumes in developing markets.
GMI Analyst View
Our discussions with industry stakeholders indicate that global pneumococcal vaccine market revenue was USD 8.1 billion in 2024. The subsequent recovery reflects normalization in channel inventory alongside resilient underlying demand for adult immunization and childhood public-health programs, supporting the market's longer-term growth outlook.
Pneumococcal Vaccine Market Trends, Growth Drivers & GMI Forecast Outlook
Expanded adult recommendations, higher-valency product launches, and broader childhood immunization coverage are reinforcing demand across major markets. Growth will depend on provider-led conversion of newly eligible adults, dependable public procurement, and the ability of manufacturers and national programs to maintain access where reimbursement, co-financing, and delivery infrastructure remain uneven.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Adult demand is moving from a risk-based clinical decision toward an age-based pathway that can be executed through primary care, employer health programs, and pharmacies. ACIP expanded its recommendation to PCV-naïve adults aged 50 years and older, replacing a framework centered on adults aged 65 years and older and certain risk groups [2]Centers for Disease Control and Prevention. "Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024." cdc.gov. That change reduces eligibility complexity, but commercial conversion will still depend on provider prompts, payer coverage, and convenient administration sites.
Public-program demand follows a different mechanism. Procurement scale, financing continuity, and operational delivery determine whether national introduction translates into administered doses. Countries that have already established childhood PCV schedules can deepen coverage through routine-service strengthening, while large birth cohorts in South Asia and other middle-income markets create meaningful volume potential for manufacturers able to compete within public tender structures.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Adult under-vaccination is likely to constrain the pace at which guideline expansion becomes realized revenue. Pneumococcal vaccination does not benefit from the recurring annual contact pattern associated with seasonal vaccines, so providers must identify eligible patients and make a deliberate recommendation during routine care. Fragmented reimbursement pathways and uneven pharmacy participation can further slow uptake, particularly among adults who do not regularly engage with preventive services.
In lower-income markets, financial transition can create a tension between strong public-health need and procurement affordability. As governments assume a greater share of vaccine financing, budget authorities may prioritize schedule continuity over faster expansion or product upgrading. Cold-chain reliability compounds this risk: enrollment in a program does not ensure vaccination if inventory cannot move consistently to remote facilities or survive last-mile distribution.
GMI Analyst View
We view the next competitive phase as a contest over guideline fit and reimbursement positioning rather than serotype count alone. Products that can demonstrate value for residual adult disease, while fitting payer and provider workflows, should be better placed to defend premium pricing. Pipeline progress matters because it shapes negotiating leverage before the next major cycle of adult schedule revisions.
Pneumococcal Vaccine Market Segment Analysis
By Vaccine Product
PCV13 generated USD 3.35 billion in the global pneumococcal vaccine market in 2025 and is projected to expand at a 0.7% CAGR (2026–2035). Its large installed base in childhood schedules and established public procurement relationships preserve demand, but adult prescribing is progressively migrating toward higher-valency alternatives where reimbursement and clinical guidance support substitution.
PCV20 is forecast to reach USD 5.5 billion by 2035 and held a 30.0% revenue share in 2025. The product benefits from a simplified adult pathway that avoids the administrative complexity of sequential vaccination, making it well suited to primary-care and retail-pharmacy settings where completion and workflow efficiency influence product selection.
Vaxneuvance accounted for a 9.0% revenue share in 2025 and is anticipated to grow at a 5.4% CAGR (2026–2035). It retains a role in markets where established sequential protocols remain clinically relevant or where reimbursement decisions have not yet moved fully to higher-valency options, although internal portfolio substitution remains a strategic constraint.
Capvaxive is expected to represent a 17.6% revenue share by 2035 and is forecast to advance at a 13.5% CAGR (2026–2035). Its commercial opportunity rests on a differentiated adult disease narrative and the ability to convert regulatory availability into reimbursement decisions, formulary placement, and provider confidence across multiple jurisdictions.
Synflorix generated USD 208 million in 2025 and is expected to hold a 1.5% revenue share by 2035. The product remains relevant in price-sensitive childhood programs where WHO prequalification, established supply arrangements, and tender competitiveness carry more weight than adult-market product differentiation.
Pneumosil is projected to reach USD 400 million by 2035 and is anticipated to expand at a 7.2% CAGR (2026–2035). India-based manufacturing and a low-cost supply model support its position in public immunization tenders, particularly where countries need sustainable PCV access as concessional financing evolves.
Pneumovax 23 generated USD 166 million in 2025 and is forecast to grow at a 1.0% CAGR (2026–2035). Its role is narrowing as single-agent higher-valency PCV regimens gain acceptance, but residual sequential schedules and institutional procurement habits should sustain a defined base of demand.
By Age Group
Infants & children younger than 5 years generated USD 3.68 billion in 2025 and are projected to grow at a 5.0% CAGR (2026–2035). This cohort remains anchored by routine childhood schedules, political prioritization of pediatric prevention, and the continuing addition of birth-cohort volume in markets where national programs are still expanding.
Adults aged 18–64 years are forecast to reach USD 5.5 billion by 2035 and are expected to advance at a 5.5% CAGR (2026–2035). The segment is increasingly shaped by age-based recommendations, workplace vaccination, and pharmacy access, with product mix skewing toward premium adult formulations in high-income markets.
The elderly population aged 65 years and older accounted for a 25.0% revenue share in 2025 and is forecast to reach USD 3.8 billion by 2035. Demand remains supported by established clinical awareness and demographic aging, although the incremental opportunity is less dependent on newly broadened eligibility than in the middle-aged adult cohort.
By Distribution Channel
Government and public programs generated USD 6.62 billion in 2025 and are expected to account for a 52.0% revenue share by 2035. This channel continues to define childhood vaccination access, but its relative revenue weight declines as adult vaccination expands through commercially reimbursed and private administration settings.
Hospital and private clinics are forecast to reach USD 3.98 billion by 2035 and are projected to grow at a 9.8% CAGR (2026–2035). These settings are important for patients with chronic conditions, specialist referrals, and older adults whose vaccination decisions remain closely tied to physician encounters.
Retail pharmacy accounted for an 8.0% revenue share in 2025 and is expected to advance at a 12.8% CAGR (2026–2035). Pharmacy-based administration improves convenience and helps convert broad adult recommendations into actual vaccinations, particularly where pharmacists can identify eligible consumers during routine preventive-care visits.
E-commerce and digital health channels are expected to account for a 6.0% revenue share by 2035 and are projected to grow at a 12.6% CAGR (2026–2035). Their role is centered on appointment coordination, prescription navigation, and directing urban consumers to administration sites rather than replacing clinical vaccination delivery.
By Vaccine Type
Pneumococcal conjugate vaccines are forecast to reach USD 15.12 billion by 2035 and represented a 98.2% revenue share in 2025. Their market leadership reflects the clinical value of conjugate technology, including durable immune response and reduced carriage, which supports their position in both pediatric schedules and modern adult immunization pathways.
Pneumococcal polysaccharide vaccines accounted for a 1.8% revenue share in 2025 and are forecast to reach USD 183 million by 2035. The category remains relevant where sequential protocols persist, but its strategic role is increasingly supplementary as health systems shift toward single-agent higher-valency conjugate options.
GMI Analyst View
We expect channel mix to become increasingly important to revenue quality. Public tenders will remain indispensable for population coverage, but retail pharmacies and private clinics are better positioned to capture adult demand at differentiated product pricing. Manufacturers with disciplined channel strategy, provider education, and reimbursement execution should benefit more than those relying solely on product breadth.
Pneumococcal Vaccine Market Regional Analysis
North America Pneumococcal Vaccine Market Analysis
North America is the leading regional market in the global pneumococcal vaccine market, generating USD 4.78 billion in 2025 and forecast to reach USD 7.1 billion by 2035. The region combines premium adult pricing with guideline-driven uptake, creating a market where reimbursement decisions, prescriber behavior, and pharmacy access have an outsized influence on value realization.
United States
The United States generated USD 4.58 billion in 2025 and is forecast to grow at a 4.0% CAGR (2026–2035). ACIP-backed adult eligibility expansion, established payer coverage, and pharmacy administration support demand, but the rate of conversion among newly eligible adults will determine the market's near-term trajectory.
Canada
Canada is forecast to reach USD 315 million by 2035 and is projected to grow at a 4.6% CAGR (2026–2035). Provincial decision-making will shape adoption timing for newer PCVs, while an established pharmacy vaccination infrastructure provides a practical route for adult-market expansion.
Europe Pneumococcal Vaccine Market Analysis
The Europe pneumococcal vaccine market is forecast to reach USD 2.1 billion by 2035 and is anticipated to expand at a 5.8% CAGR (2026–2035). Commercial progress will unfold country by country because reimbursement authority sits with national health systems and health technology assessment bodies. The European Commission authorized Capvaxive for adults in March 2025, providing a regulatory foundation for subsequent national access decisions [4]Merck & Co., Inc. "European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults." merck.com.
Germany
Germany generated USD 170 million in 2025 and is projected to grow at a 4.8% CAGR (2026–2035). The market's mature childhood base and statutory insurance system make reimbursement conditions for adult higher-valency products the principal determinant of incremental value growth.
United Kingdom
The United Kingdom is forecast to reach USD 260 million by 2035 and is expected to advance at a 5.7% CAGR (2026–2035). NHS policy and advisory review will determine how quickly newer adult products move from regulatory availability into broad programmatic use.
France
France generated USD 140 million in 2025 and is forecast to grow at a 6.5% CAGR (2026–2035). Its comparatively strong outlook reflects the potential for early reimbursement-driven adoption of higher-valency adult PCVs within a well-developed preventive-care system.
Italy
Italy is forecast to reach USD 222 million by 2035 and is expected to expand at a 5.5% CAGR (2026–2035). Regional health authority control over procurement and implementation is likely to produce a staggered adoption pattern rather than a single national inflection point.
Spain
Spain generated USD 110 million in 2025 and is projected to grow at a 5.9% CAGR (2026–2035). Autonomous-community decision-making will influence the pace of adult schedule evolution, while the established pediatric base supports continued program continuity.
Netherlands
The Netherlands is forecast to reach USD 121 million by 2035 and is anticipated to expand at a 4.2% CAGR (2026–2035). A highly vaccinated population supports stable demand, although the smaller population base limits the scale of incremental revenue compared with larger European markets.
Asia Pacific Pneumococcal Vaccine Market Analysis
The Asia Pacific pneumococcal vaccine market is expected to grow at a 6.9% CAGR (2026–2035) and reach USD 4.3 billion by 2035. The region combines public-program volume growth in large lower- and middle-income markets with premium adult demand in more developed healthcare systems, creating distinct commercial models within one regional market.
China
China is forecast to reach USD 1.43 billion by 2035 and is projected to grow at a 7.4% CAGR (2026–2035). Provincial access expansion, urban private-pay demand, and domestic manufacturing ambitions position the market as both a scale opportunity and a strategically contested arena.
India
India generated USD 350 million in 2025 and is expected to advance at an 8.2% CAGR (2026–2035). Universal Immunization Programme expansion and a large birth cohort underpin volume growth, while domestic supply capability helps improve affordability and program resilience.
Japan
Japan is forecast to reach USD 484 million by 2035 and is anticipated to grow at a 4.9% CAGR (2026–2035). The market's next stage depends on adult-program development and decisions concerning the role of higher-valency PCVs within government-supported and private vaccination pathways.
South Korea
South Korea generated USD 150 million in 2025 and is projected to expand at a 5.6% CAGR (2026–2035). A developed private-pay vaccination culture, physician recommendation networks, and strong healthcare access create favorable conditions for higher-value adult vaccination demand.
Australia
Australia is forecast to reach USD 199 million by 2035 and is expected to grow at a 5.2% CAGR (2026–2035). Public support for priority populations and the prospect of broader adult uptake provide the principal avenues for demand expansion.
Latin America Pneumococcal Vaccine Market Analysis
The Latin America pneumococcal vaccine market is forecast to reach USD 950 million by 2035 and is projected to expand at a 5.6% CAGR (2026–2035). Growth reflects the interaction of public childhood immunization, regional procurement support, and a developing private adult-vaccination market in larger urban economies.
Brazil
Brazil generated USD 200 million in 2025 and is expected to grow at a 6.6% CAGR (2026–2035). Public procurement through the national health system remains central to volume, while private clinics create an additional channel for premium adult products.
Mexico
Mexico is forecast to reach USD 211 million by 2035 and is anticipated to expand at a 5.8% CAGR (2026–2035). Universal childhood vaccination underpins baseline demand, and regulatory access to newer formulations can broaden private-clinic participation in adult immunization.
Argentina
Argentina generated USD 80 million in 2025 and is projected to grow at a 4.4% CAGR (2026–2035). Fiscal pressure and private-pay affordability constraints are likely to keep growth more closely linked to program volume than to sustained improvements in revenue per dose.
Middle East & Africa Pneumococcal Vaccine Market Analysis
The Middle East & Africa pneumococcal vaccine market generated USD 460 million in 2025 and is forecast to grow at a 6.3% CAGR (2026–2035). Gulf adult-vaccination opportunities and sub-Saharan childhood program expansion provide complementary demand sources, although financing and delivery infrastructure remain material constraints in several African markets.
Saudi Arabia
Saudi Arabia is forecast to reach USD 187 million by 2035 and is expected to advance at a 7.6% CAGR (2026–2035). Health-system investment, adult preventive-care initiatives, and private hospital access support a more premium-oriented growth profile than in most regional markets.
UAE
The UAE generated USD 70 million in 2025 and is anticipated to grow at a 7.1% CAGR (2026–2035). Its urban population, broad insurance coverage, and developed private healthcare infrastructure provide a supportive setting for adult PCV adoption.
South Africa
South Africa is forecast to reach USD 101 million by 2035 and is projected to grow at a 5.3% CAGR (2026–2035). Continued childhood program delivery remains the market's foundation, while the pace of future expansion will depend on domestic financing capacity and private-sector adult demand.
GMI Analyst View
We see Asia Pacific as the most complex regional opportunity because volume-led public immunization and premium adult vaccination are advancing at the same time. This creates substantial demand but also a wide range of price points and channel economics. The strongest commercial positions will belong to companies that can operate effectively across both tender-driven and differentiated private-market settings.
Pneumococcal Vaccine Market Share & Competitive Landscape
The global pneumococcal vaccine market share remains concentrated, with the top four manufacturers accounting for 90.6% of market revenue in 2025. Competition is increasingly centered on clinical differentiation, guideline positioning, manufacturing economics, and the ability to secure access through public tenders, private reimbursement, and pharmacy channels.
Pfizer held a 67.1% market share in 2025. Its Prevnar franchise benefits from long-standing pediatric program placement and broad prescriber familiarity, while PCV20 provides a major platform in adult vaccination. The company's pipeline activity indicates a strategy focused on retaining clinical relevance as higher-valency products redefine the premium adult segment.
Merck held a 19.0% market share in 2025. Its portfolio spans Vaxneuvance, Capvaxive, and Pneumovax 23, enabling participation across established sequential protocols and newer higher-valency adult pathways. Capvaxive's commercial potential rests on its ability to secure reimbursement and guideline support in markets where residual adult disease burden is central to product evaluation.
GlaxoSmithKline held a 2.3% market share in 2025. Synflorix remains important in selected public childhood programs, where supply reliability, prequalification, and tender economics shape purchasing decisions. The company's position is more exposed to price competition because it lacks a comparable higher-valency adult product franchise.
Serum Institute of India is expanding Pneumosil across GAVI-eligible and other price-sensitive markets. Its manufacturing-cost advantage and public-program orientation position the company to compete where affordability, reliable volume supply, and support for national immunization rollout are decisive.
Bio-Manguinhos/Fiocruz has strategic relevance as a domestic manufacturing and technology-transfer participant in Brazil's public vaccination ecosystem. Its significance lies primarily in supply security and national procurement policy rather than broad international commercial competition.
Beijing Minhai Biological Technology and Walvax Biotechnology are pursuing domestically oriented opportunities in China. Their competitive relevance will depend on clinical development progress, regulatory execution, and the ability to meet public- and private-sector demand for locally manufactured pneumococcal products.
Recent Industry Developments
Merck receives FDA approval for an expanded Capvaxive indication in high-risk children and adolescents. In June 2026, the U.S. FDA approved an additional Capvaxive indication for children and adolescents aged 2 through 17 years who have completed a primary pediatric pneumococcal vaccination series and have chronic medical conditions that increase pneumococcal disease risk. The decision was supported by Phase 3 STRIDE-13 data and expands Merck's addressable high-risk pediatric population [6]Merck & Co., Inc. "U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease." merck.com.
Pfizer initiates a pivotal pediatric program for its 25-valent pneumococcal conjugate vaccine candidate. In May 2026, Pfizer initiated a Phase 3 pediatric program for 25vPnC following positive Phase 2 results. The program underscores the company's effort to extend its product pipeline beyond PCV20 and supports continuing innovation pressure in the higher-valency PCV market [7]Pfizer Inc. "Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results." pfizer.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →